Is it time to consider a role for MRI before prostate biopsy?

被引:254
作者
Ahmed, Hashim U. [1 ]
Kirkham, Alex [2 ]
Arya, Manit [1 ]
Illing, Rowland [2 ]
Freeman, Alex
Allen, Clare [2 ]
Emberton, Mark [1 ,2 ]
机构
[1] UCL, Div Surg & Intervent Sci, London WC1E 6AU, England
[2] Univ Coll London Hosp NHS Fdn Trust, London, England
基金
英国医学研究理事会;
关键词
RADICAL RETROPUBIC PROSTATECTOMY; CANCER CORE DISTRIBUTION; PREDICTING TUMOR VOLUME; CONTRAST-ENHANCED MRI; ANTIGEN LEVELS; GLEASON SCORE; ACTIVE SURVEILLANCE; DISEASE RECURRENCE; URINARY CONTINENCE; RADIATION-THERAPY;
D O I
10.1038/nrclinonc.2009.18
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The use of MRI in prostate cancer management is controversial and current guidelines underplay its role. Technological advances over the past 5 years, however, demand a re-evaluation of this position. in this article, we propose an increased use of MRI, not only in those with a diagnosis of prostate cancer but also for men before a prostate biopsy. The use of MRI before a biopsy can serve as a triage test in men with raised serum prostate-specific antigen levels, in order to select those for biopsy with significant cancer that requires treatment. This strategy could avoid biopsy, and hence unnecessary treatment, in those with no disease or insignificant cancer. in addition, avoidance of postbiopsy artifact caused by hemorrhage will lead to better local staging accuracy, while determining more accurately the disease burden. This approach could improve risk stratification by selecting those who require adjuvant therapy or dose escalation. Furthermore, Mri evaluation of cancer burden could be important in active surveillance regimens to select those needing intervention.
引用
收藏
页码:197 / 206
页数:10
相关论文
共 105 条
  • [1] Abella H.A, 2008, DIAGN IMAGING, P36
  • [2] Ahmed HU, 2007, J UROLOGY, V177, P2395, DOI 10.1016/j.juro.2007.01.173
  • [3] Will focal therapy become a standard of care for men with localized prostate cancer?
    Ahmed, Hashim Uddin
    Pendse, Doug
    Illing, Rowland
    Allen, Clare
    van der Meulen, Jan H. P.
    Emberton, Mark
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (11): : 632 - 642
  • [4] AHMED HU, 2006, J UROLOGY, V176, P2432
  • [5] 20-year outcomes following conservative management of clinically localized prostate cancer
    Albertsen, PC
    Hanley, JA
    Fine, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17): : 2095 - 2101
  • [6] The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy
    Antunes, AA
    Srougi, M
    Dall'oglio, MF
    Crippa, A
    Campagnari, JC
    Leite, KRM
    [J]. BJU INTERNATIONAL, 2005, 96 (09) : 1258 - 1263
  • [7] Atalar Ergin, 2005, Magn Reson Imaging Clin N Am, V13, P491, DOI 10.1016/j.mric.2005.04.012
  • [8] Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: Value of MR imaging
    Beyersdorff, D
    Taupitz, M
    Winkelmann, B
    Fischer, T
    Lenk, S
    Loening, SA
    Hamm, B
    [J]. RADIOLOGY, 2002, 224 (03) : 701 - 706
  • [9] Radical prostatectomy versus watchful waiting in early prostate cancer
    Bill-Axelson, A
    Holmberg, L
    Ruutu, M
    Häggman, M
    Andersson, SO
    Bratell, S
    Spångberg, A
    Busch, C
    Nordling, S
    Garmo, H
    Palmgren, J
    Adami, HO
    Norlén, BJ
    Johansson, JE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (19) : 1977 - 1984
  • [10] OPTIMIZATION OF PROSTATE CARCINOMA STAGING - COMPARISON OF IMAGING AND CLINICAL METHODS
    BONI, RAH
    BONER, JA
    DEBATIN, JF
    TRINKLER, F
    KNONAGEL, H
    VONHOCHSTETTER, A
    HELFENSTEIN, U
    KRESTIN, GP
    [J]. CLINICAL RADIOLOGY, 1995, 50 (09) : 593 - 600